CN103550071A - Anti-ageing gene oligopeptide-containing preparation and application of preparation to cosmetics - Google Patents
Anti-ageing gene oligopeptide-containing preparation and application of preparation to cosmetics Download PDFInfo
- Publication number
- CN103550071A CN103550071A CN201310562915.7A CN201310562915A CN103550071A CN 103550071 A CN103550071 A CN 103550071A CN 201310562915 A CN201310562915 A CN 201310562915A CN 103550071 A CN103550071 A CN 103550071A
- Authority
- CN
- China
- Prior art keywords
- gene
- hydrolytic collagen
- recombinaton
- gene recombinaton
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Cosmetics (AREA)
Abstract
The invention provides an anti-ageing gene oligopeptide-containing preparation and an application of the preparation to cosmetics. The preparation is prepared by compounding gene oligopeptide key components, auxiliary materials and preparation raw materials. Gene oligopeptide is selected from one or a combination of genetic recombination hydrolyzed collagen dipeptide, genetic recombination hydrolyzed collagen tripeptide, genetic recombination hydrolyzed collagen tetrapeptide, genetic recombination hydrolyzed collagen pentapeptide, genetic recombination hydrolyzed collagen hexapeptide, first genetic recombination hydrolyzed collagen, second genetic recombination hydrolyzed collagen, third genetic recombination hydrolyzed collagen, genetic recombination gene protein, first genetic recombination hydrolyzed hyaluronic acid and second genetic recombination hydrolyzed hyaluronic acid.
Description
Technical field
The invention belongs to the crossing domain of cosmetics, Chinese medicine technology and biotechnology, relate to a kind of preparation with senile-resistant efficacy gene oligopeptide complex preparation prescription, and the application in cosmetic field.
Background technology
Low stimulation effect type cosmetics are the focuses that society chases always.But the effect type cosmetics on present society always do not reach everybody requirement.Effect prescription, from Chinese medicine theory, is found by our company, guarantees the effect of its product; Utilize modern advanced technologies---gene biochemical technology, produce the critical materials in composing prescription preparation, guarantee the low irritant of product.
Just based on above-mentioned two theories, breach, in the research and development achievement of the cosmetics prescription in conjunction with for many years, especially, in the advantage in cosmetics defying age field, is looked for from this prescription by our company, found that oligopeptide, at the aspect such as anti-aging, delaying senility and mild wrinkle in advance, has magical especially effect.The expert in the fields such as some biological engineering of company organization and genetic engineering, researchs and develops these critical materialses, is write separately these achievements as patent and reports.
Summary of the invention
The object of the present invention is to provide a kind of prescription with senile-resistant efficacy gene oligopeptide complex preparation and cosmetics.
Prescription of the present invention, is divided into three parts, and one is critical materials formula, and it two is critical materials accessory formula, and it three is preparations shaping raw material.
Critical materials prescription is by gene recombinaton hydrolytic collagen dipeptides, gene recombinaton hydrolytic collagen tripeptides, gene recombinaton hydrolytic collagen tetrapeptide, gene recombinaton hydrolytic collagen pentapeptide, gene redundancy hydrolytic collagen six peptides, gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton gene protein
gene recombinaton hydrolysis hyaluronic acid
with gene recombinaton hydrolysis hyaluronic acid
one or more combination.Single or the combination of these raw materials makes each efficacy of drugs produce synergism, thereby skin is played to antidotal effect, but these material combination are only verified on individual molecule cytobiology.In order better to obtain the anti-aging product of biological significance, must add critical materials adjuvant, with it, reach best defying age effect.
Critical materials accessory formula is by pollen extract, ceramide, glycolic acid, kojic acid, lactic acid, citric acid, tartaric acid, vitamin A, vitamin B, dipotaccium glycyrrhizate, azelaic acid, Flos Rosae Rugosae quintessence oil, clove oil, Essential Oil From Pine Needles, Herba Lysimachiae foenum-graeci quintessence oil, the one or more combination in sweet orange oil.Single or the combination of these raw materials makes the checking of critical materials prescription on individual molecule cytobiology can under human body skin condition, be able to smooth realization.But the cosmetics as simple, are also nowhere near, can't be satisfactory at aspects such as moisturizing, skinfeel, dosage form and degree of smearing.So also will add preparations shaping raw material.
Preparations shaping raw material is to take thickening agent, emulsifying agent, package agent, wetting agent, emollient, aromatic, antiseptic and solvent as main industrial chemicals.Specifically, thickening agent can be aluminium-magnesium silicate, guar gum, HANSHENGJIAO, arabic gum, carrageenan, tragacanth, hydroxyethyl-cellulose, methylcellulose, ethyl cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, PVP, sodium polyacrylate, hydroxypropyl level cellulose, sodium alginate, carbomer, modification carbomer etc.Emulsifying agent can be sodium lauryl sulphate, stearic acid and salt, polyethers etc.Package agent is white oil, vaseline, lanoline, biological lipid, silicone oil and each vegetable oil wax etc.Wetting agent is glycerol, propylene glycol, butanediol, carbamide, Sorbitol, glucitol, Mel, PCA, Aloe extract etc.Emollient is cetyl glyceride, Semen Ricini wet goods.Aromatic comprises quintessence oil and daily chemical essence.Antiseptic is the antiseptic that < < cosmetics health standard > > confirms.Solvent is mainly ethanol, pure water, Polyethylene Glycol and deionized water etc.By the raw material described in these, one or more form preparations shaping raw material.
The cosmetics of being prepared by critical materials, critical materials adjuvant and preparations shaping raw material, can have following dosage form: stock solution, health film, facial film, cleansing milk, day cream, late frost, lipstick, foundation emulsion, eye shadow, cosmetic water and elite etc.
Key component proportioning (by weight percentage, as follows): gene recombinaton hydrolytic collagen dipeptides 0～15%, gene recombinaton hydrolytic collagen tripeptides 0～15%, gene recombinaton hydrolytic collagen tetrapeptide 0～15%, gene recombinaton hydrolytic collagen pentapeptide 0～15%, gene redundancy hydrolytic collagen six peptides 0～15%, gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
0～15%, gene recombinaton gene protein
gene recombinaton hydrolysis hyaluronic acid
with gene recombinaton hydrolysis hyaluronic acid
The preferred proportion of key component exists:
Gene recombinaton hydrolytic collagen dipeptides 0～12.5%, gene recombinaton hydrolytic collagen tripeptides 0～12.5%, gene recombinaton hydrolytic collagen tetrapeptide 0～12.5%, gene recombinaton hydrolytic collagen pentapeptide 0～12.5%, gene redundancy hydrolytic collagen six peptides 0～12.5%, gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton gene protein
gene recombinaton hydrolysis hyaluronic acid
with gene recombinaton hydrolysis hyaluronic acid
The optimum material proportion of key component is:
Gene recombinaton hydrolytic collagen dipeptides 0～8.88%, gene recombinaton hydrolytic collagen tripeptides 0～8.88%, gene recombinaton hydrolytic collagen tetrapeptide 0～8.88%, gene recombinaton hydrolytic collagen pentapeptide 0～8.88%, gene redundancy hydrolytic collagen six peptides 0～8.88%, gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton gene protein
gene recombinaton hydrolysis hyaluronic acid
with gene recombinaton hydrolysis hyaluronic acid
Critical materials ratio of adjuvant is:
Pollen extract 0～5%, ceramide 0～5%, glycolic acid 0～5%, kojic acid 0～5%, lactic acid 0～5%, citric acid 0～5%, tartaric acid 0～5%, vitamin A 0～5%, vitamin B 0～5%, dipotaccium glycyrrhizate 0～5%, azelaic acid 0～5%, Flos Rosae Rugosae quintessence oil 0～5%, clove oil 0～5%, Essential Oil From Pine Needles 0～5%, Herba Lysimachiae foenum-graeci quintessence oil 0～5%, sweet orange oil 0～5%.
The preferred proportion of critical materials adjuvant exists:
Pollen extract 0～3.5%, ceramide 0～5%, glycolic acid 0～5%, kojic acid 0～5%, lactic acid 0～5%, citric acid 0～5%, tartaric acid 0～5%, vitamin A 0～5%, vitamin B 0～5%, dipotaccium glycyrrhizate 0～5%, azelaic acid 0～5%, Flos Rosae Rugosae quintessence oil 0～3.5%, clove oil 0～3.5%, Essential Oil From Pine Needles 0～3.5%, Herba Lysimachiae foenum-graeci quintessence oil 0～3.5%, sweet orange oil 0～3.5%.
The optimum material proportion of critical materials adjuvant is:
Pollen extract 0～1.5%, ceramide 01～3.5%, glycolic acid 1～5%, kojic acid 1～5%, lactic acid 1～5%, citric acid 1～5%, tartaric acid 1～5%, retinol1～5%, vitamin B1～5%, dipotaccium glycyrrhizate 1～5%, azelaic acid 1～5%, Flos Rosae Rugosae quintessence oil 0～2.5%, clove oil 0～2.5%, Essential Oil From Pine Needles 0～2.5%, Herba Lysimachiae foenum-graeci quintessence oil 0～2.5%, sweet orange oil 0～2.5%.
Preparations shaping proportioning raw materials is:
Aluminium-magnesium silicate (0～0.5%), guar gum (0～0.5%), HANSHENGJIAO (0～0.5%), arabic gum (0～0.5%), carrageenan (0～0.5%), tragacanth (0～0.5%), hydroxyethyl-cellulose (0～0.5%), methylcellulose (0～0.5%), ethyl cellulose (0～0.5%), sodium carboxymethyl cellulose (0～0.5%), polyvinyl alcohol (0～0.5%), PVP (0～0.5%), sodium polyacrylate (0～0.5%), hydroxypropyl level cellulose (0～0.5%), sodium alginate (0～0.5%), carbomer (0～0.5%), modification carbomer (0～0.5%)/sodium lauryl sulphate (0～5%), stearic acid and salt thereof (0～5%), polyethers (0～5%), white oil (0～15%), vaseline (0～15%), lanoline (0～15%), biological lipid (0～15%), silicone oil (0～15%), vegetable oil (0～15%), glycerol (0～15%), propylene glycol (0～15%), butanediol (0～15%), carbamide (0～15%), Sorbitol (0～15%), glucitol (0～15%), Mel (0～15%), PCA (0～15%), Aloe extract (0～15%), cetyl glyceride (0～10%), Oleum Ricini (0～10%), aromatic (0～0.5%, antiseptic (0～0.5%), ethanol (0～98%), pure water (0～98%), Polyethylene Glycol (0～98%), deionized water (0～98%).By described raw material, one or more form preparations shaping raw material.
The hybrid technique of prescription of the present invention:
By above-mentioned critical materials, critical materials adjuvant and preparations shaping raw material mix homogeneously.
Prescription of the present invention, can be prepared into clean class, skin type and beautify the cosmetics such as class according to the common process of preparing cosmetics.
The specific embodiment
The proportioning of critical materials prescription of the present invention, critical materials adjuvant and preparations shaping raw material is described below by specific embodiment.
Embodiment 1～8 is critical materials of the present invention prepares prescription, and specifically in Table 1, unit by weight percentage.
The preparation of table 1 embodiment 1～8 critical materials prescription
Preparation method: by gene recombinaton raw material mix homogeneously proportionally.
Embodiment 9～16 is critical materials adjuvant of the present invention prepares prescription, and specifically in Table 2, unit by weight percentage.
The preparation of table 2 embodiment 9～16 critical materials adjuvant prescriptions
Preparation method: by gene recombinaton raw material mix homogeneously proportionally.
Embodiment 17～26 is anti-aging cosmetics of the present invention prepares prescription, and specifically in Table 3, unit by weight percentage.Embodiment 17～embodiment 21 is toiletries frost emulsifiable paste series products.Embodiment 22～embodiment 23 is water preparations of cosmetics.Embodiment 24～embodiment 26 is elite products of cosmetics.Embodiment 19～embodiment 25 is mask product of cosmetics
Each prescription of system of table 3 embodiment 17～26 anti-aging cosmetics
Preparation method: by gene recombinaton raw material mix homogeneously proportionally.
Embodiment 17～26 gained cosmetics defying age measure of merit:
Healthy normal trial volunteer 100 people of choosing, men and women half and half, and the age was from 30 years old to 65 years old.Be divided at random 10 groups, every group of 10 people, respectively control Example 17 to 26.
Embodiment 27
Test crowd uses twice every day, and the morning and evening respectively once, is only used at left half of face, and right half of face is used the placebo that does not contain key component.Use the half of face in corresponding left and right 30 days.
Testing result:
| Test crowd | Very obvious crowd | Obvious crowd | Not obvious crowd |
| Embodiment 17 | 3 | 4 | 3 |
| Embodiment 18 | 4 | 4 | 2 |
| Embodiment 19 | 4 | 8 | 2 |
| Embodiment 20 | 4 | 3 | 3 |
| Embodiment 21 | 5 | 5 | 0 |
[0046]?
| Embodiment 22 | 5 | 5 | 0 |
| Embodiment 23 | 4 | 4 | 2 |
| Embodiment 24 | 3 | 4 | 3 |
| Embodiment 25 | 3 | 4 | 3 |
| Embodiment 26 | 5 | 4 | 1 |
Result of the test shows, prescription of the present invention has good result in a short time to defying age.
Embodiment 28
Test crowd uses twice every day, and the morning and evening respectively once, is only used at left half of face, and right half of face is used the placebo that does not contain key component.Use the half of face in corresponding left and right 90 days.
Testing result:
| Test crowd | Very obvious crowd | Obvious crowd | Not obvious crowd |
| Embodiment 17 | 8 | 2 | 0 |
| Embodiment 18 | 9 | 1 | 0 |
| Embodiment 19 | 9 | 1 | 0 |
| Embodiment 20 | 10 | 0 | 0 |
| Embodiment 21 | 10 | 0 | 0 |
| Embodiment 22 | 10 | 0 | 0 |
| Embodiment 23 | 10 | 0 | 0 |
| Embodiment 24 | 8 | 1 | 1 |
| Embodiment 25 | 7 | 2 | 1 |
| Embodiment 26 | 9 | 0 | 1 |
Result of the test shows, prescription of the present invention has good result to defying age in mid-term.
Implementation column 29
Test crowd uses twice every day, and the morning and evening respectively once, is only used at left half of face, and right half of face is used the placebo that does not contain key component.Use half a year, the half of face in corresponding left and right.
Testing result:
| Test crowd | Very obvious crowd | Obvious crowd | Not obvious crowd |
| Embodiment 17 | 9 | 0 | 1 |
| Embodiment 18 | 10 | 0 | 0 |
| Embodiment 19 | 10 | 0 | 0 |
| Embodiment 20 | 10 | 0 | 0 |
| Embodiment 21 | 10 | 0 | 0 |
[0057]?
| Embodiment 22 | 10 | 0 | 0 |
| Embodiment 23 | 10 | 0 | 0 |
| Embodiment 24 | 10 | 0 | 0 |
| Embodiment 25 | 10 | 0 | 0 |
| Embodiment 26 | 10 | 0 | 0 |
Result of the test shows to have good result in prescription of the present invention is long-term to defying age.
Claims (10)
1. a prescription with senile-resistant efficacy gene oligopeptide complex preparation cosmetics, its prescription is divided into three parts, and one is critical materials formula, and it two is critical materials accessory formula, and it three is preparations shaping composition of raw materials.
2. the critical materials formula with the prescription of defying age gene oligopeptide formulation cosmetic as claimed in claim 1, is characterized in that:
Formula: by weight percentage, as follows.
Gene recombinaton hydrolytic collagen dipeptides 0～15%, gene recombinaton hydrolytic collagen tripeptides 0～15%, gene recombinaton hydrolytic collagen tetrapeptide 0～15%, gene recombinaton hydrolytic collagen pentapeptide 0～15%, gene redundancy hydrolytic collagen six peptides 0～15%, gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton gene protein
gene recombinaton hydrolysis hyaluronic acid
with gene recombinaton hydrolysis hyaluronic acid
3. the optimization formula of the critical materials of the prescription with defying age gene oligopeptide formulation cosmetic as claimed in claim 1, is characterized in that:
Gene recombinaton hydrolytic collagen dipeptides 0～12.5%, gene recombinaton hydrolytic collagen tripeptides 0～12.5%, gene recombinaton hydrolytic collagen tetrapeptide 0～12.5%, gene recombinaton hydrolytic collagen pentapeptide 0～12.5%, gene redundancy hydrolytic collagen six peptides 0～12.5%, gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton gene protein
0～12.5%, gene recombinaton hydrolysis hyaluronic acid
with gene recombinaton hydrolysis hyaluronic acid
4. the optimum formula of the critical materials of the prescription with defying age gene oligopeptide formulation cosmetic as claimed in claim 1, is characterized in that:
Gene recombinaton hydrolytic collagen dipeptides 0～8.88%, gene recombinaton hydrolytic collagen tripeptides 0～8.88%, gene recombinaton hydrolytic collagen tetrapeptide 0～8.88%, gene recombinaton hydrolytic collagen pentapeptide 0～8.88%, gene redundancy hydrolytic collagen six peptides 0～8.88%, gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton hydrolytic collagen
gene recombinaton gene protein
0～8.88%%, gene recombinaton hydrolysis hyaluronic acid
with gene recombinaton hydrolysis hyaluronic acid
5. the critical materials accessory formula with the prescription of defying age gene oligopeptide formulation cosmetic as claimed in claim 1, is characterized in that:
Pollen extract 0～5%, ceramide 0～5%, glycolic acid 0～5%, kojic acid 0～5%, lactic acid 0～5%, citric acid 0～5%, tartaric acid 0～5%, vitamin A 0～5%, vitamin B 0～5%, dipotaccium glycyrrhizate 0～5%, azelaic acid 0～5%, Flos Rosae Rugosae quintessence oil 0～5%, clove oil 0～5%, Essential Oil From Pine Needles 0～5%, Herba Lysimachiae foenum-graeci quintessence oil 0～5%, sweet orange oil 0～5%.
6. the critical materials Optimization of Adjuvant formula with the prescription of defying age gene oligopeptide formulation cosmetic as claimed in claim 1, is characterized in that:
Pollen extract 0～3.5%, ceramide 0～5%, glycolic acid 0～5%, kojic acid 0～5%, lactic acid 0～5%, citric acid 0～5%, tartaric acid 0～5%, vitamin A 0～5%, vitamin B 0～5%, dipotaccium glycyrrhizate 0～5%, azelaic acid 0～5%, Flos Rosae Rugosae quintessence oil 0～3.5%, clove oil 0～3.5%, Essential Oil From Pine Needles 0～3.5%, Herba Lysimachiae foenum-graeci quintessence oil 0～3.5%, sweet orange oil 0～3.5%.
7. the critical materials adjuvant optimum formula with the prescription of defying age gene oligopeptide formulation cosmetic as claimed in claim 1, is characterized in that:
Pollen extract 0～1.5%, ceramide 01～3.5%, glycolic acid 1～5%, kojic acid 1～5%, lactic acid 1～5%, citric acid 1～5%, tartaric acid 1～5%, retinol1～5%, vitamin B1～5%, dipotaccium glycyrrhizate 1～5%, azelaic acid 1～5%, Flos Rosae Rugosae quintessence oil 0～2.5%, clove oil 0～2.5%, Essential Oil From Pine Needles 0～2.5%, Herba Lysimachiae foenum-graeci quintessence oil 0～2.5%, sweet orange oil 0～2.5%.
8. the preparations shaping composition of raw materials with the prescription of defying age gene oligopeptide formulation cosmetic as claimed in claim 1, is characterized in that:
Formula: by weight percentage
Aluminium-magnesium silicate (0～0.5%), guar gum (0～0.5%), HANSHENGJIAO (0～0.5%), arabic gum (0～0.5%), carrageenan (0～0.5%), tragacanth (0～0.5%), hydroxyethyl-cellulose (0～0.5%), methylcellulose (0～0.5%), ethyl cellulose (0～0.5%), sodium carboxymethyl cellulose (0～0.5%), polyvinyl alcohol (0～0.5%), PVP (0～0.5%), sodium polyacrylate (0～0.5%), hydroxypropyl level cellulose (0～0.5%), sodium alginate (0～0.5%), carbomer (0～0.5%), modification carbomer (0～0.5%)/sodium lauryl sulphate (0～5%), stearic acid and salt thereof (0～5%), polyethers (0～5%), white oil (0～15%), vaseline (0～15%), lanoline (0～15%), biological lipid (0～15%), silicone oil (0～15%), vegetable oil (0～15%), glycerol (0～15%), propylene glycol (0～15%), butanediol (0～15%), carbamide (0～15%), Sorbitol (0～15%), glucitol (0～15%), Mel (0～15%), PCA (0～15%), Aloe extract (0～15%), cetyl glyceride (0～10%), Oleum Ricini (0～10%), aromatic (0～0.5%, antiseptic (0～0.5%), ethanol (0～98%), pure water (0～98%), Polyethylene Glycol (0～98%), deionized water (0～98%).
9. the dosage form with the prescription of defying age gene oligopeptide formulation cosmetic as claimed in claim 1, is characterized in that: can prepare stock solution, health film, facial film, day cream, late frost, lipstick, foundation emulsion, eye shadow, cosmetic water and elite etc.
10. the prescription with defying age gene oligopeptide formulation cosmetic as claimed in claim 1, is characterized in that: by the common process of preparing cosmetic product, can be prepared into product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310562915.7A CN103550071A (en) | 2013-11-14 | 2013-11-14 | Anti-ageing gene oligopeptide-containing preparation and application of preparation to cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310562915.7A CN103550071A (en) | 2013-11-14 | 2013-11-14 | Anti-ageing gene oligopeptide-containing preparation and application of preparation to cosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103550071A true CN103550071A (en) | 2014-02-05 |
Family
ID=50004561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310562915.7A Pending CN103550071A (en) | 2013-11-14 | 2013-11-14 | Anti-ageing gene oligopeptide-containing preparation and application of preparation to cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103550071A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948525A (en) * | 2014-04-23 | 2014-07-30 | 广州宝生堂化妆品有限公司 | Anti-aging active composition for epidermis |
| CN104962597A (en) * | 2015-07-09 | 2015-10-07 | 严宜昌 | Method for extracting collagen polypeptide from tortoise shells and application of collagen polypeptide in preparation of sleeping mask |
| CN106109261A (en) * | 2016-07-19 | 2016-11-16 | 仲恺农业工程学院 | Whitening skin lightening breast and preparation method thereof |
| CN107669548A (en) * | 2017-10-28 | 2018-02-09 | 安徽孔氏奇医药科技有限公司 | A kind of crease-resistant Wash-free mask and preparation method thereof |
| CN108070020A (en) * | 2016-11-11 | 2018-05-25 | 上海莱妃化妆品有限公司 | A kind of anti-aging, the cosmetic composition for accelerating cell metabolism |
| CN110494116A (en) * | 2017-03-27 | 2019-11-22 | 赢创德固赛有限公司 | It is used to prepare the method and product of the formulation containing ceramide |
| CN111658573A (en) * | 2020-06-17 | 2020-09-15 | 广州艾尔亿医药有限公司 | Human-like serum protein preparation for regenerative medicine cosmetology |
| CN114642608A (en) * | 2021-03-10 | 2022-06-21 | 广州星途投资运营集团有限公司 | Formula of gene recombination anti-aging gene oligopeptide compound reagent |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1190580A (en) * | 1998-02-24 | 1998-08-19 | 郑文恺 | Skin protective cosmetics containing cell growth factor |
| CN103102407A (en) * | 2013-01-29 | 2013-05-15 | 西安益力欣生物科技有限公司 | Genetic recombinant human-like collagen |
| CN103300382A (en) * | 2013-05-28 | 2013-09-18 | 孙国勇 | Anti-aging collagen peptide nutrient |
| CN103388017A (en) * | 2013-08-06 | 2013-11-13 | 国家海洋局第三海洋研究所 | Preparation technology of fish skin collagen oligopeptide |
-
2013
- 2013-11-14 CN CN201310562915.7A patent/CN103550071A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1190580A (en) * | 1998-02-24 | 1998-08-19 | 郑文恺 | Skin protective cosmetics containing cell growth factor |
| CN103102407A (en) * | 2013-01-29 | 2013-05-15 | 西安益力欣生物科技有限公司 | Genetic recombinant human-like collagen |
| CN103300382A (en) * | 2013-05-28 | 2013-09-18 | 孙国勇 | Anti-aging collagen peptide nutrient |
| CN103388017A (en) * | 2013-08-06 | 2013-11-13 | 国家海洋局第三海洋研究所 | Preparation technology of fish skin collagen oligopeptide |
Non-Patent Citations (4)
| Title |
|---|
| 成军: "《现代细胞外基质分子生物学》", 30 June 2012, article "胶原蛋白", pages: 17-22 * |
| 李俊: "《美容药物学》", 31 August 2006, article "延缓皮肤衰老药", pages: 161-172 * |
| 李国英，等: "《胶原化学》", 30 April 2013, article "胶原在生物体组织中的分布，胶原、明胶和水解胶原蛋白的区别", pages: 13-15 * |
| 汤克勇: "《胶原物理与化学》", 31 January 2012, article "胶原在美容化妆品中的应用", pages: 436-438 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948525A (en) * | 2014-04-23 | 2014-07-30 | 广州宝生堂化妆品有限公司 | Anti-aging active composition for epidermis |
| CN103948525B (en) * | 2014-04-23 | 2016-04-06 | 广州宝生堂化妆品有限公司 | Anti-aging active composition for epidermis |
| CN104962597A (en) * | 2015-07-09 | 2015-10-07 | 严宜昌 | Method for extracting collagen polypeptide from tortoise shells and application of collagen polypeptide in preparation of sleeping mask |
| CN106109261A (en) * | 2016-07-19 | 2016-11-16 | 仲恺农业工程学院 | Whitening skin lightening breast and preparation method thereof |
| CN108070020A (en) * | 2016-11-11 | 2018-05-25 | 上海莱妃化妆品有限公司 | A kind of anti-aging, the cosmetic composition for accelerating cell metabolism |
| CN108070020B (en) * | 2016-11-11 | 2021-07-13 | 上海莱妃化妆品有限公司 | A cosmetic composition with antiaging and cell metabolism promoting effects |
| CN110494116A (en) * | 2017-03-27 | 2019-11-22 | 赢创德固赛有限公司 | It is used to prepare the method and product of the formulation containing ceramide |
| CN107669548A (en) * | 2017-10-28 | 2018-02-09 | 安徽孔氏奇医药科技有限公司 | A kind of crease-resistant Wash-free mask and preparation method thereof |
| CN111658573A (en) * | 2020-06-17 | 2020-09-15 | 广州艾尔亿医药有限公司 | Human-like serum protein preparation for regenerative medicine cosmetology |
| CN114642608A (en) * | 2021-03-10 | 2022-06-21 | 广州星途投资运营集团有限公司 | Formula of gene recombination anti-aging gene oligopeptide compound reagent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103550071A (en) | Anti-ageing gene oligopeptide-containing preparation and application of preparation to cosmetics | |
| CN109937031B (en) | Kangaroo claw extract for cosmetic use | |
| US11684559B2 (en) | Topical cosmetic treatment of skin and scalp and corresponding active ingredient based on an extract of Apium graveolens | |
| CN111182914A (en) | Compositions and methods for improving skin laxity and body contour | |
| CN103705393A (en) | Preparation with selective whitening spot-removing efficacy and application thereof in cosmetics | |
| JP2011519353A (en) | Active ingredients that stimulate fibroblast proliferation and / or activity | |
| KR20160131387A (en) | Composition for skin care | |
| CN109562082A (en) | Anti-acne compsn and application method | |
| CN105451710A (en) | Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails | |
| TW201420107A (en) | Extract of Phalaenopsis amabilis petals, and the preparation process and uses thereof | |
| KR20210018388A (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| BR112016023571B1 (en) | methods to reduce the signs of skin aging in an individual, to increase the adipogenesis of an individual's face and body and to increase the lipogenesis of an individual's face and body | |
| WO2015140679A1 (en) | Cosmetic use of an extract of mirabilis jalapa | |
| BR112016022734B1 (en) | method for reducing cell oxidative stress, method for reducing cell apoptosis induced by oxidative stress and method for reducing cell photodamage | |
| KR20110012601A (en) | Cosmetic compositions, soaf for body, soaf for scalp and shampoo for scalp using an extract of a sweetflag | |
| BR112016023653B1 (en) | topical composition | |
| KR101734801B1 (en) | Methods of reducing signs of skin aging using a combination of extracts | |
| AU2014392686B2 (en) | Topical composition including a combination of extracts for reducing signs of skin aging | |
| JP2018127407A (en) | Epidermis normalization agent as well as external preparations and cosmetics containing the same | |
| US10548835B2 (en) | Methods of reducing the signs of skin aging | |
| JP2018145106A (en) | Skin external compositions | |
| BR112016023895B1 (en) | methods to reduce the signs of skin aging, to increase the adipogenesis of the face and body and to increase the lipogenesis of the face and body | |
| JP2017155029A (en) | Soymilk-fermented product | |
| JP2024000465A (en) | External composition for skin or hair care | |
| JP2004352634A (en) | Cosmetic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Shaanxi Dongda Biochemical Technology Co., Ltd. Document name: Notification that Application Deemed to be Withdrawn |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140205 |